| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A minimal physiologically based pharmacokinetic model for high-dose methotrexate
|
Pesenti, Giuseppe
|
|
|
88 |
4 |
p. 595-606
|
artikel
|
| 2 |
A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers
|
Eto, Takashi
|
|
|
88 |
4 |
p. 713-722
|
artikel
|
| 3 |
Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment
|
Kumari, Neha
|
|
|
88 |
4 |
p. 565-594
|
artikel
|
| 4 |
Correction to: Changes in expression of lysosomal membrane proteins in leucocytes of cancer patients treated with tyrosine kinase inhibitors
|
Pastvova, N.
|
|
|
88 |
4 |
p. 753
|
artikel
|
| 5 |
Effect of carboplatin dose capping on survival in recurrent breast, ovary and head and neck cancers: a single institutional retrospective study
|
Roy, Pritha
|
|
|
88 |
4 |
p. 731-740
|
artikel
|
| 6 |
Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug–drug interactions with oral targeted therapy
|
Leenhardt, Fanny
|
|
|
88 |
4 |
p. 723-729
|
artikel
|
| 7 |
Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase
|
Panetta, John C.
|
|
|
88 |
4 |
p. 655-664
|
artikel
|
| 8 |
Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma
|
Öman, Mikael
|
|
|
88 |
4 |
p. 619-631
|
artikel
|
| 9 |
Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors
|
Maguire, William F.
|
|
|
88 |
4 |
p. 643-654
|
artikel
|
| 10 |
Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management
|
Bellesoeur, Audrey
|
|
|
88 |
4 |
p. 741-751
|
artikel
|
| 11 |
Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma
|
Schultz, Chad R.
|
|
|
88 |
4 |
p. 607-617
|
artikel
|
| 12 |
Prospective clinical trial testing COXEN-based gene expression models of chemosensitivity in dogs with spontaneous osteosarcoma
|
Gustafson, Daniel L.
|
|
|
88 |
4 |
p. 699-712
|
artikel
|
| 13 |
Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug
|
Hong, Cho Rong
|
|
|
88 |
4 |
p. 673-687
|
artikel
|
| 14 |
Targeting cPLA2α inhibits gastric cancer and augments chemotherapy efficacy via suppressing Ras/MEK/ERK and Akt/β-catenin pathways
|
Liao, Yingying
|
|
|
88 |
4 |
p. 689-697
|
artikel
|
| 15 |
The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer
|
Liao, Michael Z.
|
|
|
88 |
4 |
p. 665-672
|
artikel
|
| 16 |
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells
|
Hua, Jun
|
|
|
88 |
4 |
p. 633-642
|
artikel
|
Tijdschrift beschrijving